Pharmaceutical

OncBioMune Pharmaceuticals addressed shareholders with a corporate update indicating the company is now involved in nearly 50 drug candidates.

OncBioMune Pharmaceuticals (OTCQB:OBMP) addressed shareholders with a corporate update indicating the company is now involved in nearly 50 drug candidates.
As quoted in the press release:

When OncBioMune chose to enter the public markets in late in September 2015, management was charged with two primary directives to build shareholder value. One was to advance ProscaVax through a phase 1 study into mid-stage trials with the ultimate goal of late-stage research and commercialization as the world’s first therapeutic prostate cancer vaccine. The second was to employ an aggressive acquisition strategy for a variety of purposes, including generating revenue to fund R&D activity and additional acquisitions. Approximately one and a half year later, the Company continues to effectively execute on this business model.
“We’re very proud of all that we have accomplished in a very short period of time so far in 2017,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “We’re are hitting on all cylinders, but really feel like we are only beginning to hit our stride. As final preparations transpire to commence the two trials of ProscaVax, we’re extremely active in discussions to acquire, license or partner for drugs in Mexico and neighboring markets. At this moment, there are a total of 48 drugs/drug candidates that are already under our control for specific markets or are the subject of negotiations. There is a lot of work in front of us to finalize agreements and bring products to market, but all is going according to design with revenue coming in and deals in the works that can bolster revenue many fold in the coming years as ProscaVax moves down the clinical path. We’re more confident than ever that we’ll look back on 2017 as a transformational year for our company by maintaining our course and continuing to successfully meet milestones.”

Click here to read the full press release.

Source: www.marketwired.com

Featured

MARKETS

Markets
TSX20659.97+127.79
TSXV720.32+5.66
DOW32883.89+246.70
S&P 5004116.54+58.70
NASD11988.70+248.05
ASX7105.90-49.30

COMMODITIES

Commodities
Gold1852.22-0.84
Silver22.05+0.03
Copper4.30+0.05
Palladium2067.00+59.00
Platinum951.00+2.00
Oil113.44-0.65
Heating Oil3.86+0.01
Natural Gas8.69-0.20

DOWNLOAD FREE REPORTS

×